Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Investigational therapies for hypercholesterolemia.

Gerald H Tomkin1, Daphne Owens1

  • 1a Diabetes Institute of Ireland , Beacon Clinic and Trinity College , Dublin 2 , Ireland.

Expert Opinion on Investigational Drugs
|April 4, 2017
PubMed
Summary

New therapeutic targets and drugs are emerging to combat dyslipidemia, a major risk factor for cardiovascular disease. This review explores novel pathways and treatments, including antisense RNA, microRNA, and monoclonal antibodies, offering hope for improved clinical outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Abbreviated lipid guidelines for clinical practice : Based on ESC lipid guidelines 2019 and ESC cardiovascular disease prevention in clinical practice guidelines 2021.

Irish journal of medical science·2023
Same author

Obesity diabetes and the role of bile acids in metabolism.

Journal of translational internal medicine·2017
Same author

Dyslipidaemia of diabetes and the intestine.

World journal of diabetes·2015
Same author

Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors.

World journal of diabetes·2014
Same author

Investigational therapies for the treatment of atherosclerosis.

Expert opinion on investigational drugs·2014
Same author

The chylomicron: relationship to atherosclerosis.

International journal of vascular medicine·2011

Area of Science:

  • Biochemistry
  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Cardiovascular diseases (CVD) pose a significant global health burden.
  • Dyslipidemia is a key modifiable risk factor for CVD, necessitating improved therapeutic strategies.
  • Current treatments for dyslipidemia have limitations, highlighting the need for novel approaches.

Purpose of the Study:

  • To review recent advancements in understanding cholesterol and triglyceride metabolism.
  • To examine emerging therapeutic targets and novel drug candidates for dyslipidemia.
  • To assess the clinical trial data and potential of new treatments for cardiovascular risk reduction.

Main Methods:

  • Literature review of recent scientific publications and clinical trial results.
Keywords:
) PCSK9: low density lipoproteinApolipoprotein A1Apolipoprotein ClllLDL receptor: microsomal triglyceride transfer protein (MTP)Niemann Pick C1-like1 (NPC1-L1)Triglyceridecholesteryl ester transfer protein (CETP)diabetesdyslipidaemialipoprotein (a)low density lipoprotein LDL

Related Experiment Videos

  • Analysis of new pathways in lipid metabolism.
  • Examination of novel therapeutic agents, including small molecules, antisense RNA, microRNA, and monoclonal antibodies.

    • Main Results:

    • Identification of novel molecular targets in lipid metabolism.
    • Evaluation of new drugs demonstrating efficacy in preclinical and early clinical studies.
    • Review of approved and investigational therapies showing promise in reducing cardiovascular endpoints.

    Conclusions:

    • Emerging targets and therapies offer significant potential for improving dyslipidemia management.
    • Antisense RNA, microRNA, and monoclonal antibodies represent promising new modalities.
    • The field of dyslipidemia therapeutics is rapidly evolving, with a focus on novel mechanisms to combat atherosclerosis.